Predict your next investment

HEALTHCARE | Pharmaceuticals / Drugs
sutrobio.com

See what CB Insights has to offer

Founded Year

2004

Stage

IPO | IPO

Total Raised

$180.7M

Date of IPO

9/27/2018

Market Cap

0.85B

Stock Price

19.01

About Sutro Biopharma

Sutro Biopharma is a clinical stage drug discovery, development and manufacturing company focused on leveraging its integrated cell-free protein synthesis platform, XpressCF, to create a broad variety of protein therapeutics for cancer and autoimmune disorders.

Sutro Biopharma Headquarter Location

310 Utah Avenue Suite 150

South San Francisco, California, 94080,

United States

650-392-8412

Latest Sutro Biopharma News

Week in Review: Hansoh Signs $456 Million Deal for siRNA Products

Oct 16, 2021

publication date: Oct 16, 2021  |  Shanghai South Korea 's OliX Pharma (KOSDAQ: 226950) (see story ). The two companies will collaborate using OliX's GalNAc-asiRNA platform for various liver-based targets that are implicated in cardiovascular, metabolic and other indications. Hansoh will make an upfront payment of $6.5 million and up to $450 million in milestones. OliX will continue to hold rights to the products in the rest of the world. Abbisko (HK: 2256), a  Hong Kong  to support its small molecule therapies for cancer (see story) . At the IPO price, Abbisko has a $1.1 billion market capitalization. Formed in 2016, Abbisko has developed a portfolio of 14 drug candidates, five of them at clinical stage. Its lead program, a pan-FGFR inhibitor aimed at urothelial carcinoma, is partnered with AstraZeneca. The company plans to start Phase Ib/II China trials for the candidate soon. Shanghai BioNova Pharma acquired an option for  China South San Francisco 's Sutro Biopharma (NSDQ: STRO) in a $204 million agreement (see story ). BioNova will make a $4 million payment for the option, and it will pay up to $200 million to exercise the option and make milestone payments. It will develop STRO-001 to treat non-Hodgkin's lymphoma, multiple myeloma and leukemia. Sutro will also receive tiered, double-digit royalties. Sciwind Biosciences, a  Hangzhou  biopharma focused on metabolic disease, closed a $70 million Series C funding . Sciwind will use the proceeds to advance clinical development of its three leading GLP-1 receptor agonist candidates for NASH and other metabolic conditions. (see story ). The financing round was co-led by IDG Capital, Loyal Valley Capital and LYFE Capital. Chance Pharma of Hangzhou, an inhalation therapy company, completed a $30 million Series C financing led by new investor Lapam Capital (see story ). Chance intends to use the capital to advance its R&D, start new business collaborations and accelerate the construction of a manufacturing facility. Also participating in the C round were new investors CMS Capital and HEDA BioVenture and existing investor Guozhong Capital. Earlier this year, Chance signed a deal with Aerami Therapeutics to acquire greater  China  rights for a drug device combination product aimed at Pulmonary Arterial Hypertension. GV20 Oncotherapy, a Cambridge, MA-Shanghai biotech, completed a Series B round of undisclosed size to advance its lead immuno-oncology antibody candidate into the clinic (see story ). GV20 claims unique expertise in novel target identification and antibody drug discovery in the immuno-oncology field. The company applies its novel genomics platform and AI techniques to speed up antibody drug discovery. The B round was led by Coatue Management, and included existing investors IDG Capital, 3W Investment, Watson Capital, Linear Capital and others. Eucure Bio, a subsidiary of  Beijing North America (see story ). Eucure says YH001 has enhanced ADCC and CDC efficacy that differentiate the candidate from other CTLA-4 products. Tracon will be responsible for the clinical development and markteting of YH001 in multiple oncology indications in the US while Eucure Biopharma will supply YH001. Tracon will pay escalating double digit royalties on net sales to Eucure Biopharma. Company News  Beijing 's BeiGene (NSDQ: BGNE; HK: 06160)) ) and Celgene (now Bristol-Myers) is falling apart (NYSE: BMY) (see story ). The companies are arguing over BeiGene's  China  distribution rights for Abraxane, a nanoparticle albumin–bound form of paclitaxel, used to treat several forms of cancer. BeiGene acquired  China China  commercial team as part of the deal that also gave Celgene ex-China rights to BeiGene's PD-1 candidate. Unfortunately, a  China South San Francisco 's Twist Bioscience (NSDQ: TWST) have launched their Pan-Cancer Methylation Panel in global markets (see story ). The Pan-Cancer Panel was developed over a two-year period by AnchorDx in collaboration with Twist. It includes DNA methylation library preparation and targeted enrichment for next-gen sequencing (NGS). The panel covers 47 disease entities from The Cancer Genome Atlas and 31 cancer types such as lung, breast and colorectal cancers. The two companies will market the product globally for global cancer screening and scientific research. Zai Lab (NSDQ: ZLAB; HK: 9688) of  Shanghai  will collaborate with Geneseeq Technology, a Toronto-China company, to integrate cutting-edge NGS services into clinical trials and advance precision care (see story ). The two companies will form business relationships based on Geneseeq's clinical trial patient recruitment, central laboratory testing, companion diagnostics development and marketing services for Zai's cancer candidates. Zai has three cancer products approved in  China Trials and Approvals  China  trial of its selective internal radiation therapy in patients with hepatocellular carcinoma (HCC) (see story ). One year ago, Sirtex filed an NDA in  China  for its SIR-Spheres® Y-90 resin microspheres, a targeted radiation therapy, for liver metastases from colorectal cancer. The Y-90 resin microspheres are designed to accumulate in the liver, where they deliver a 40-times larger dose of radiation without affecting normal tissue. In 2018,  China 's CDH Holding paid $1.9 billion to acquire Sirtex. Suzhou Kintor Pharma (HK: 9939) was approved to start a China Phase I trial of its ALK-1 antibody in combination with Bristol-Myers Squibb's PD-1, nivolumab (Opdivo®), in patients with advanced hepatocellular carcinoma (see story ). The ALK-1 antibody is a fully human IgG2 neutralizing mAb that inhibits ALK-1/TGF-β signal transduction, interrupting tumor angiogenesis and changing the tumor microenvironment. In 2018, Kintor acquired an exclusive global license from Pfizer for the candidate in all oncological applications. Disclosure: none.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Sutro Biopharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sutro Biopharma is included in 5 Expert Collections, including Pharma Startups.

P

Pharma Startups

6,549 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

C

Cancer Therapeutics

1,179 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharmaceuticals

14,139 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

C

Cancer

3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

S

Synthetic Biology

235 items

Companies involved in design and development of new biological parts, devices, and systems; as well as the re-design of existing biological systems.

Sutro Biopharma Patents

Sutro Biopharma has filed 57 patents.

The 3 most popular patent topics include:

  • Clusters of differentiation
  • Immunology
  • Immune system
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/14/2017

8/24/2021

Immunology, Immune system, Monoclonal antibodies, Clusters of differentiation, Antibodies

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

6/14/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

8/24/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Immunology, Immune system, Monoclonal antibodies, Clusters of differentiation, Antibodies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sutro Biopharma Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sutro Biopharma Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.